prikaz prve stranice dokumenta Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma
  Preuzmi
PDF 523.66 KB
Znanstveni rad - Izvorni znanstveni rad
Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma
Pathology, Research and Practice, 206 (2010), 10; 695-699. https://doi.org/10.1016/j.prp.2010.05.013
Demirović, Alma; Džombeta, Tihana; Tomas, Davor; Spajić, Borislav; Pavić, Ivana; Hudolin, Tvrtko; Milošević, Milan; Čupić, Hrvoje; Krušlin, Božo

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Demirović, A., Džombeta, T., Tomas, D., Spajić, B., Pavić, I., Hudolin, T. ... Krušlin, B. (2010). Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. Pathology, Research and Practice, 206. (10), 695-699. doi: 10.1016/j.prp.2010.05.013

Demirović, Alma, et al. "Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma." Pathology, Research and Practice, vol. 206, br. 10, 2010, str. 695-699. https://doi.org/10.1016/j.prp.2010.05.013

Demirović, Alma, Tihana Džombeta, Davor Tomas, Borislav Spajić, Ivana Pavić, Tvrtko Hudolin, Milan Milošević, Hrvoje Čupić i Božo Krušlin. "Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma." Pathology, Research and Practice 206, br. 10 (2010): 695-699. https://doi.org/10.1016/j.prp.2010.05.013

Demirović, A., et al. (2010) 'Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma', Pathology, Research and Practice, 206(10), str. 695-699. doi: 10.1016/j.prp.2010.05.013

Demirović A, Džombeta T, Tomas D, Spajić B, Pavić I, Hudolin T, i sur.. Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. Pathology, Research and Practice [Internet]. 15.10.2010. [pristupljeno 22.11.2024.];206(10):695-699. doi: 10.1016/j.prp.2010.05.013

A. Demirović, et al., "Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma", Pathology, Research and Practice, vol. 206, br. 10, str. 695-699, Listopad 2010. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:095787. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:095787
Podaci o radu
Naslov (engleski)Immunohistochemical expression of tumor antigens MAGE-A3/4 and NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma
AutorAlma Demirović
AutorTihana Džombeta
AutorDavor Tomas
AutorBorislav Spajić
AutorIvana Pavić
AutorTvrtko Hudolin
AutorMilan Milošević
AutorHrvoje Čupić
AutorBožo Krušlin
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
The distinction between renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC), especially the eosinophilic variant, can often be difficult. Our study has documented for the first time the expression of MAGE-A3/4 and NY-ESO-1 cancer testis antigens (CTAs) in these tumors. A total of 35 patients (17 ROs and 18 ChRCCs) were included in the study. Two antibodies were used for immunohistochemical staining: 57B recognizing multiple MAGE-A and D8.38 recognizing NY-ESO-1 CTAs. Fifteen (88.2%) samples of RO stained positively for both MAGE-A3/4 and NY-ESO-1 antigens. Regarding ChRCC, seven (38.9%) stained positively for MAGE-A3/4 and six (33.3%) for NY-ESO-1 antigens. Median MAGE-A3/4 expression was moderately positive in RO and negative in ChRCC. The difference in MAGE-A3/4 expression between two tumor groups was significant (P=0.0013). Median NY-ESO-1 expression was strongly positive in RO and negative in ChRCC. The difference in NY-ESO-1 expression between two tumor groups was also significant (P=0.0008). Our study has shown that RO had a significantly higher expression of both CTAs. However, additional research is needed to clarify their potential diagnostic implications.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaPathology, Research and Practice
Brojčani podacivol. 206, br. 10, str. 695-699
p-ISSN0344-0338
DOIhttps://doi.org/10.1016/j.prp.2010.05.013
URN:NBNurn:nbn:hr:105:095787
Datum objave publikacije2010-10-15
URL dokumentahttps://doi.org/ Gustav Fischer Verlag
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 11:45:54